Wait JCM, Vaccharajani N, Mitroka J, Jemal M, Khan S, Bonacorsi SJ, Rinehart JK,
Iyer RA. Metabolism of [^14 C]gemopatrilat after oral administration to rats, dogs,
and humans. Drug Metab Dispos 2006;34:961–970.
Wang L, Zhang D, Swaminathan A, Xue Y, Cheng PT, Wu S, Mosqueda-Garcia R,
Aurang C, Everett DW, Humphreys WG. Glucuronidation as a major metabolic
clearance pathway of^14 C-labeled muraglitazar in humans: metabolic profiles in
subjects with or without bile collection. Drug Metab Dispos 2006;34:427–439. Epub
2005 Dec 20–28.
Wen X, Wang J-S, Backman JT, Kivisto KT, Neuvonen PJ. Gemfibrozil is a potent
inhibitor of human cytochrome P450 2C9. Drug Metab Dispos 2001;29:1359–1361.
WHO.Use of ionizing radiation and radionuclides on human beings for medical
research, training and nonmedical purpose.WHO Publication611;1977.
Williams JA, Hurst SI, Bauman J, Jones BC, Hyland R, Gibbs JP, Obach RS, Ball SE.
Reaction phenotyping in drug discovery: moving forward with confidence? Curr
Drug Metab 2003;4:527–534.
Williams JA, Hyland R, Jones BC, Smith DA, Hurst S, Goosen TC, Peterkin V, Koup
JR, Ball SE. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a
pharmacokinetic explanation for typically observed low exposure (AUCi/AUC)
ratios. Drug Metab Dispos 2004;32:1201–1208.
Yamamoto T, Suzuki A, Kohno Y. Application of microtiter plate assay to evaluate
inhibitory effects of various compounds on nine cytochrome P450 isoforms and to
estimate their inhibition patterns. Drug Metab Pharmacokinet 2002;17:437–448.
Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro
inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease
inhibitors and the relationship of this property toin vivobilirubin glucuronidation.
Drug Metab Dispos 2005;33:1729–1739.
Zhang D, Wang L, Chandrasena G, Ma L, Zhu M, Zhang H, Davis CD, Humphreys
WG. Involvement of multiple cytochrome P450 and UDP-glucuronosyltransferase
enzymes in thein vitrometabolism of muraglitazar. Drug Metab Dispos 2007;35:139–
149.
Zhang D, Raghavan N, Chando T, Gambardella J, Fu Y, Zhang DX, Unger S,
Humphreys WG. LC-MS/MS-based approach for obtaining exposure estimates of
metabolites in early clinical trials by using radioactive metabolites as reference
standards. Drug Metab Lett 2007a; in print.
Zhang H, Zhang D, Ray K. A software filter to remove interference ions from drug
metabolites in accurate mass liquid chromatography/mass spectrometric analysis.
J Mass Spectrom 2003;38:1110–1112.
Zhang ZY, Wong YN. Enzyme kinetics for clinically relevant CYP inhibition. Curr
Drug Metab 2005;6:241–257.
Zhou S, Chan E, Lim LY, Boelsterli UA, Li SC, Wang J, Zhang Q, Huang M, Xu A.
Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450
3A4. Curr Drug Metab 2004;5:415–442.
Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL.
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin
Pharmacokinet 2005;44:279–304.
REFERENCES 285